Norway backs downs over plan to exclude anticancer drugs from coverageBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f1707 (Published 14 March 2013) Cite this as: BMJ 2013;346:f1707
- Anders Hansen
After strong public reaction, Norway’s health minister, Jonas Gahr Støre, has reversed a decision to exclude the two anticancer drugs ipilimumab and abiraterone from the list of drugs covered by national insurance.
Ipilimumab is a human monoclonal antibody used against inoperable melanoma or in cases where the melanoma has spread. The drug has been shown to prolong the life of most patients by two to six …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial